Cargando…

Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study

Detalles Bibliográficos
Autores principales:	Georgakopoulos, Jorge R., Mufti, Asfandyar, Vender, Ron, Yeung, Jensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American Academy of Dermatology, Inc. 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361079/ https://www.ncbi.nlm.nih.gov/pubmed/32679279 http://dx.doi.org/10.1016/j.jaad.2020.07.021

Ejemplares similares

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

34223 Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: A multicenter retrospective cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2022)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series
por: Phung, Michelle, et al.
Publicado: (2018)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
por: Vender, Ronald, et al.
Publicado: (2022)

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Psoriasis, biologic therapy, and the pandemic of the 21st century
por: Nogueira, Miguel, et al.
Publicado: (2020)

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2021)

COVID-19 and wound care: A Canadian perspective
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Reply to: “Skin damage among health care workers managing coronavirus disease 2019”
por: Maliyar, Khalad, et al.
Publicado: (2020)

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers
por: Vender, Ronald B., et al.
Publicado: (2022)

Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators?
por: Metko, Dea, et al.
Publicado: (2023)

Tapinarof for the treatment of psoriasis
por: Nogueira, Sofia, et al.
Publicado: (2022)

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies
por: Duquette, Pierre, et al.
Publicado: (2019)

Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2023)

Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Differences in Practice Patterns and Payments for Female and Male Dermatologists: A Canadian Population-Based Study Over 3 Decades
por: Georgakopoulos, Jorge R., et al.
Publicado: (2022)

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
por: Pilon, Dominic, et al.
Publicado: (2022)

Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors
por: Schmidt, Lana, et al.
Publicado: (2023)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians
por: Drakos, Anastasia, et al.
Publicado: (2022)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Systemic Role for Vitamin D in the Treatment of Psoriasis and Metabolic Syndrome
por: Fu, Lisa Wenyang, et al.
Publicado: (2011)

Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review
por: Sachdeva, Muskaan, et al.
Publicado: (2021)

Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
por: Lynde, Charles W., et al.
Publicado: (2022)

Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
por: Messori, Andrea, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9k4hdu0lvuv39bvl1sldtio5n9